Combinations of anti-gip antibodies and incretins and uses thereof
AssigneeHelicore Biopharma, Inc.
InventorsJames Patterson, Jing Liang, Paul Kierstead
Life of this patent
Estimating the term…
Abstract
Provided for herein are anti-GIP antibodies, or antigen-binding fragments thereof. Conjugates of the anti-GIP antibodies, or antigen-binding fragments thereof, to biologically active peptides are also provided. Pharmaceutical compositions of the, anti-GIP antibodies, or antigen-binding fragments thereof, biologically active peptides, combinations thereof, or conjugates thereof are also provided. Methods of using the embodiments and compositions provided for herein are also provided.
Claims28
A conjugate, comprising an anti-glucose-dependent insulinotropic polypeptide (GIP) antibody, or an antigen-binding fragment thereof, conjugated to a biologically active peptide, wherein the biologically active peptide comprises a glucagon like peptide 1 receptor (GLP-1R) agonist.
(canceled)
-14. (canceled)
(canceled)
A conjugate comprising an anti-glucose-dependent insulinotropic polypeptide (GIP) antibody, or an antigen-binding fragment thereof, conjugated to a biologically active peptide,
- wherein the biologically active peptide is conjugated to the anti-GIP antibody, or antigen-binding fragment thereof, through one or more substitutions of a canonical amino acid to a cysteine,
- wherein the one or more substitution of a canonical amino acid to a cysteine comprises an E272C, K290C, or S442C mutation in a heavy chain of the antibody, and/or a K149C or V205C substitution in a light chain of the antibody, and
- wherein the biologically active peptide comprises a glucagon like peptide 1 receptor (GLP-1R) agonist.
(canceled)
-40. (canceled)
-43. (canceled)
-47. (canceled)
(canceled)
Dependencies are inferred from the claim text.